New hope for rare disease: experimental drug targets PMM2-CDG
Disease control
Completed
This study tested an experimental drug called GLM101 in 27 people with PMM2-CDG, a rare genetic condition that causes problems with balance and movement. Participants received different doses of the drug intravenously over 24 weeks. The main goal was to see if the drug improves c…
Phase: PHASE2 • Sponsor: Glycomine, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC